Iovance Biotherapeutics (NASDAQ:IOVA – Free Report) had its target price upped by Citizens Jmp from $8.00 to $12.00 in a research report sent to investors on Friday morning,Benzinga reports. The firm currently has a market outperform rating on the biotechnology company’s stock.
IOVA has been the subject of several other reports. UBS Group lifted their price objective on Iovance Biotherapeutics from $7.00 to $8.00 and gave the stock a “neutral” rating in a research report on Tuesday. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Iovance Biotherapeutics in a research note on Tuesday, September 29th. Zacks Research upgraded Iovance Biotherapeutics from a “hold” rating to a “strong-buy” rating in a report on Monday, October 26th. Robert W. Baird boosted their price target on Iovance Biotherapeutics from $6.00 to $11.00 and gave the company a “neutral” rating in a research note on Thursday, October 8th. Finally, Wells Fargo & Company increased their price target on Iovance Biotherapeutics from $14.00 to $18.00 and gave the stock an “overweight” rating in a report on Wednesday, September 30th. One equities research analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating, three have assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, Iovance Biotherapeutics presently has an average rating of “Moderate Buy” and an average target price of $13.80.
Read Our Latest Analysis on IOVA
Iovance Biotherapeutics Stock Up 3.9%
Shares of NASDAQ:IOVA traded up $0.30 during trading on Friday, hitting $8.04. 12,935,434 shares of the company were exchanged, compared to its average volume of 15,291,578. Iovance Biotherapeutics has a 1-year low of $2.08 and a 1-year high of $15.37. The company has a market capitalization of $3.64 billion, a P/E ratio of -15.17 and a beta of 0.88. The business’s 50 day moving average is $11.37 and its 200-day moving average is $5.97.
Iovance Biotherapeutics (NASDAQ:IOVA – Get Free Report) last released its quarterly earnings results on Thursday, November 5th. The biotechnology company reported ($0.05) earnings per share for the quarter, topping the consensus estimate of ($0.09) by $0.04. The company had revenue of $121.47 million for the quarter, compared to analysts’ expectations of $115.98 million. Iovance Biotherapeutics had a negative return on equity of 40.51% and a negative net margin of 89.11%. Iovance Biotherapeutics’s revenue for the quarter was up 64.8% on a year-over-year basis. As a group, sell-side analysts anticipate that Iovance Biotherapeutics will post -0.45 earnings per share for the current year.
Hedge Funds Weigh In On Iovance Biotherapeutics
A number of large investors have recently modified their holdings of IOVA. Clearwater Capital Advisors LLC bought a new position in shares of Iovance Biotherapeutics in the third quarter valued at approximately $322,000. Russell Investments Group Ltd. grew its stake in shares of Iovance Biotherapeutics by 165.7% in the 3rd quarter. Russell Investments Group Ltd. now owns 513,032 shares of the biotechnology company’s stock worth $7,603,000 after acquiring an additional 319,979 shares in the last quarter. Brighton Jones LLC raised its holdings in shares of Iovance Biotherapeutics by 5.1% in the third quarter. Brighton Jones LLC now owns 40,069 shares of the biotechnology company’s stock valued at $594,000 after purchasing an additional 1,954 shares during the last quarter. Pictet Asset Management Holding SA raised its holdings in shares of Iovance Biotherapeutics by 867.6% in the third quarter. Pictet Asset Management Holding SA now owns 416,539 shares of the biotechnology company’s stock valued at $6,043,000 after purchasing an additional 373,491 shares during the last quarter. Finally, Kestra Advisory Services LLC lifted its position in shares of Iovance Biotherapeutics by 25.2% during the third quarter. Kestra Advisory Services LLC now owns 42,150 shares of the biotechnology company’s stock valued at $625,000 after purchasing an additional 8,483 shares in the last quarter. 77.03% of the stock is currently owned by institutional investors.
Iovance Biotherapeutics News Summary
Here are the key news stories impacting Iovance Biotherapeutics this week:
- Positive Sentiment: Iovance reported record third-quarter revenue of about $122 million, beating estimates, while its loss of $0.05 per share was narrower than the expected $0.09. Amtagvi U.S. revenue grew about 77% year over year, gross margin reached a company-record 60%, and management reaffirmed its 2026 revenue outlook. These results point to growing commercial traction and improving economics. Iovance third-quarter results
- Positive Sentiment: Barclays raised its price target from $18 to $19 and kept an “overweight” rating; Citizens JMP raised its target from $8 to $12 and maintained a “market outperform” rating. The upgrades reflect more optimistic analyst views on IOVA’s prospects. Barclays ratings Citizens JMP ratings
- Positive Sentiment: Lifileucel received FDA Fast Track designation following promising sarcoma trial data, potentially supporting development in an additional cancer indication. Lifileucel Fast Track news
- Negative Sentiment: NSCLC results were mixed: the objective response rate was 24.6% across 69 evaluable patients, slightly below a prior interim result. That may temper expectations for this opportunity, although a biomarker-selected subgroup showed a higher 59.1% response rate and a trial is underway. Iovance clinical outlook
About Iovance Biotherapeutics
Iovance Biotherapeutics, Inc (NASDAQ: IOVA) is a biotechnology company focused on developing and commercializing personalized cell therapies for patients with cancer. Its technology is based on tumor-infiltrating lymphocytes (TILs), immune cells collected from a patient’s tumor, expanded outside the body, and reinfused to help attack cancer cells.
The company’s lead product, Amtagvi (lifileucel), is an autologous TIL therapy approved in the United States for certain adults with unresectable or metastatic melanoma that has progressed following prior treatment.
Read More
- Five stocks we like better than Iovance Biotherapeutics
- Dutch Bros Gave Wall Street What It Wanted, So Why Did the Stock Crater?
- Astera Labs Just Crushed Earnings—So Why Are Analysts Cutting Price Targets?
- Sandisk Shares Are Oversold: Bargain or Value Trap?
- IonQ’s Record Revenue Includes a Big SkyWater Boost: Does That Change the Story?
Receive News & Ratings for Iovance Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Iovance Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
